相关实验视频

Updated: Jan 10, 2026

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Induction of Ocular Surface Inflammation and Collection of Involved Tissues

Published on: August 4, 2022

聚乙烯甘醇色胺降低了贝赫塞特病中NETosis和免疫光过活化

Fang Jia¹, Xiaoli Wu², Huiyang Sheng³

¹Implantology Center of Stomatological Hospital, School of Stomatology, Southern Medical University, 366 Jiangnan Road, Guangzhou, 510280, People's Republic of China. jialynn36@163.com.

European journal of medical research

|November 27, 2025

概括

聚乙烯甘洛酸 (PEX168) 通过抑制活性氧物种 (ROS) 和炎症酶活性来降低贝赫特病中的中性粒细胞过活化和中性粒细胞外陷 (NETosis),为自身免疫性疾病提供了潜在的治疗方法.

科学领域:

免疫学免疫学免疫学
血管炎症血管炎症
自免疫性疾病自免疫性疾病

背景情况:

中性粒细胞过活化和NETosis是贝赫塞特病 (BD) 中血管炎症的关键驱动因素.
已被认可化在BD病变发生中的作用,但葡萄糖样-1受体激动剂 (GLP-1RA) 对中性粒细胞失调的影响仍未得到研究.

研究的目的:

为了研究聚乙烯甘醇洛克森化物 (PEX168),GLP-1 RA,对中性粒细胞激活和相关的炎症途径在贝赫塞特病的影响.

主要方法:

利用了BD患者和健康捐赠者的中性粒细胞,以及一种小鼠BD模型.
采用西部涂抹,流细胞计 (ROS),免疫组织化学,传输电子显微镜和免疫光学来评估NETosis, pyroptosis 和炎症酶激活.

主要成果:

根据剂量,PEX168减少了中性粒细胞的过活化,NETosis标记物 (CitH3,NE,MPO) 和ROS的产生.
在较高度下观察到细胞超结构的保存和NLRP3-caspase-1-IL-1β通路的抑制.
在低度下,PEX168没有诱导热和通过NF-κB表现出双相免疫调节.

结论:

PEX168通过抑制ROS和调节上游炎症体通路来减轻中性粒细胞过活化和BD中的NETosis.
这些发现表明GLP-1RAs,就像PEX168一样,可能是针对中性粒细胞驱动的自身免疫疾病的向疗法.

关键词:

贝赫塞特病是一种疾病.过度活化过度活化中性粒细胞外细胞陷聚乙烯糖醇色酸的使用热灭菌的发生.

更多相关视频

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Author Spotlight: Investigating the Potential of Chinese Herbal Medicinal Active Dioscin in Treating IgA Nephropathy

Published on: October 13, 2023

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Dynamic Adhesion Assay for the Functional Analysis of Anti-adhesion Therapies in Inflammatory Bowel Disease

Published on: September 20, 2018

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...

Drugs for Treatment of Diarrhea-Predominant IBS

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...